A TERT promoter mutation is a genetic change in the so-called promoter region of the TERT gene. This change can cause cells to grow and divide in an uncontrolled way.
What is behind the term?
The TERT gene contains the instructions for making an enzyme called telomerase. Telomerase plays an important role in protecting the ends of chromosomes, which are known as telomeres. Normally, the TERT gene is barely active in most cells of the body. Only certain cells, such as stem cells or germ cells, use telomerase to divide more frequently than usual.
The promoter is a section that sits in front of the actual gene and works like a switch. It decides whether the gene is turned on or off. With a TERT promoter mutation, this switch changes so that the TERT gene is permanently or more strongly switched on. This causes cells to produce more telomerase than they should.
Why is this change so significant?
A TERT promoter mutation is described particularly often in connection with various types of cancer. It appears, for example, in certain brain tumours (such as glioblastomas), liver cancer, skin cancer (melanoma), and bladder cancer. The mutation causes cancer cells to become "immortal": they can keep dividing because their telomeres do not get shorter. This is a key difference from normal body cells, which can only divide a limited number of times.
For most people, a TERT promoter mutation is not a chance finding but appears in connection with a tumour diagnosis. It is usually discovered during specialist genetic testing when a tumour is already present.
What does this mean for treatment?
Whether and how a TERT promoter mutation affects treatment depends strongly on the type of tumour involved. In some cases, this information can help doctors better understand how the tumour is likely to behave. With some cancers, it is known that tumours carrying this mutation may grow more aggressively or return more quickly. This can influence treatment decisions, for example how intensively surgery, radiotherapy, or medication is used.
There are currently no targeted medicines that work specifically against TERT promoter mutations. However, researchers are working to find ways to block telomerase activity in tumour cells in a targeted way.
What questions and worries come up?
A diagnosis involving a TERT promoter mutation raises many questions. A common concern is whether the mutation can be inherited or whether it means the tumour will be harder to treat. In most cases, this is what is called a somatic mutation. This means it developed during a person's lifetime in individual cells of the body and was not present from birth or passed on through inheritance.
A TERT promoter mutation on its own is not a disease but a characteristic that cancer cells can develop in certain types of tumour. It is therefore not a cause for concern if it is found by chance with no connection to a tumour condition, which in practice almost never happens.
How is a TERT promoter mutation detected?
To identify such a mutation, tissue from the tumour is usually examined. Modern molecular biology methods can search specifically for changes in the TERT gene. This often happens as part of a comprehensive genetic analysis of the tumour, with the aim of finding the best possible treatment.
A doctor's letter or test result might then state, for example: "TERT promoter mutation detected" or "TERT promoter mutation positive". This gives an indication of how the tumour may behave and can be taken into account during further treatment.
What does this mean for everyday life?
Outside of a tumour condition, a detected TERT promoter mutation has no direct impact on everyday life. It is not a general risk factor for cancer and is not inherited. The information is most important for the treating doctors, to help them plan the right treatment.
Anyone who receives a tumour diagnosis that includes a TERT promoter mutation should know that research in this area is moving forward quickly. New findings may in the future lead to more targeted and effective treatments. Until then, treatment remains tailored to the specific type of tumour and follows the best available medical standards.
